Q1 2024: Complete dosing in the single ascending dose and multiple ascending dose cohorts of the randomized, double-blind, placebo-controlled Phase 1 trial of Intravenous AK006 in healthy volunteers. Q1 2024: Initiate the randomized, double-blind, placebo-controlled subcutaneous AK006 cohort in healthy volunteers. Q2 2024: Report SAD and MAD safety, pharmacokinetics, and pharmacodynamic results from the Phase 1 IV AK006 trial in healthy volunteers, including data to confirm Siglec-6 receptor occupancy in skin biopsy samples. Q2 2024: Initiate the randomized, double-blind, placebo-controlled Phase 1 trial of IV AK006 in patients with chronic spontaneous urticara. Q3 2024: Report subcutaneous AK006 safety, PK, and PD results from the Phase 1 trial in healthy volunteers, including data to confirm Siglec-6 receptor occupancy in skin biopsy samples. Year End 2024: Report topline data from the Phase 1 trial of IV AK006 in patients with CSU.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALLK:
